Moderna stock slips as raised outlook faces pipeline test

Moderna reported a return to quarterly profitability on November 6, while management raised its 2026 revenue outlook. In an investor update from Moderna, Chief Financial Officer Jamey Mock said third-quarter revenue grew 29 percent to 1.3 billion US dollars and cash costs declined 10 percent to 1.0 billion US dollars.

Higher Outlook, Greater Execution Test

Moderna now expects 2026 revenue to grow 15 to 25 percent, compared with its previous outlook of up to 10 percent. The company also lifted its year-end cash and investments outlook to 8.1 billion to 8.3 billion US dollars from 4.7 billion to 5.2 billion US dollars.

The improved financial framework gives Moderna more room to fund its product pipeline, but it also raises the execution bar. Vaccine demand, international partnerships and the rollout of newer respiratory products remain important to sustaining the recovery beyond one profitable quarter.

Pipeline Milestones Set Next Markers

Moderna said its pivotal mRNA-3927 study in propionic acidemia has reached target enrollment, with data expected by year-end. Initial clinical data for mRNA-2808 in multiple myeloma are scheduled for an oral presentation at the American Society of Hematology meeting from December 12 to 15.

The company and Merck also presented Phase 3 results for intismeran with pembrolizumab in patients with completely resected stage IIB-IV melanoma. The oncology portfolio offers a longer-term diversification path, although its commercial contribution still depends on clinical progress and regulatory decisions.

Late Session Quote

Moderna stock traded at 224.45 euros on Lang & Schwarz at 16:40 CET on Wednesday, November 11, 2026, 1.49 percent below the 227.85-euro quote in our November 11 report at 13:23 CET. This intraday comparison is separate from the Xetra close.

The U.S. market backdrop remains relevant as investors assess Moderna's recovery and growth pipeline.

More news and analyses on Moderna stock